Evidence map›Paper›PMID 32831966›Full record

ArticleNuclear medicine and molecular imaging2020

Aysar Khalaf, Nader Hirmas, Farah Anwer, Akram Al-Ibraheem

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Nuclear medicine and molecular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. False Positive Findings ofMolecular imaging and radionuclide therapy · 2025
    Article
  2. Nuclear medicine and molecular imaging · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Aysar KhalafDepartment of Nuclear Medicine, King Hussein Cancer Center, Amman, Jordan.
Nader HirmasDepartment of Nuclear Medicine,, Essen University Hospital, University of Duisburg-Essen, Essen, Germany.
Farah AnwerDepartment of Nuclear Medicine, King Hussein Cancer Center, Amman, Jordan.
Akram Al-IbraheemDepartment of Nuclear Medicine, King Hussein Cancer Center, Amman, Jordan.ORCID 0000-0002-0978-4716
King Hussein Cancer Center · JOEssen University Hospital · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-ossifying fibroma (NOF) is a common benign bone tumor with a high probability of occurrence in children and adolescents. It is commonly seen in the metaphysis of long bones, eccentrically located, and can coexist with other malignant tumors such as neuroendocrine tumors (NET). To date, plain radiographs play a major role in the diagnosis of these benign bone tumors. Herein, we report the case of a 13-year-old male patient who was diagnosed with pulmonary NET and underwent right lung lobectomy for a hilar mass which later revealed a well-differentiated NET. The follow-up

Indexed as

68Ga DOTA-TOCBenign bone tumorNon-ossifying fibromaPositron emission tomography and computed tomographyRight lung neuroendocrine tumor

Identifiers

PMID32831966
PMCPMC7429592
OpenAlexW3039670587

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.